Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $33.96M rose 78.2% year over year, behind the +226.8% change in trailing-twelve-month gross profit. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +108.4% a year.

Context

  • Gross profit amounted to 84.5% of revenue in FY2025, up 15.9 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +78.2% toward the trailing-twelve-month pace of +226.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.96M+4.1% QoQ
Last fiscal yearDec 2025
$89.99M+455.7% YoY
LTMMar 2026
$104.57M+226.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78.2%——
1 year+455.7%——
3-year CAGR+108.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
89.99M USD
Year-over-year change
+455.7%
4-year CAGR
+35.6%

Gross Profit vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 gross profit of $104.57M is the 5th highest of the 11 companies compared; the peer median is -$276K.
  • Its year-over-year change of +226.8% is the highest of 9, against a peer median of +17.6%.
  • Gross profit amounts to 85.5% of revenue for ZVRA, versus a peer median of 85.5%.
ZVRA Competitors Peer median
Gross Profit for ZVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$3.62B +37.2%+24.2%97.8%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$3.03B -14.7%+6.5%64.2%
ALKSAlkermes plcLTM Sep 2026$1.45B +11.0%+12.7%82.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$731.41M +24.2%+3.6%88.1%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$104.57M +226.8%+108.4%85.5%
GHRSGH Research PLCLTM Mar 2026-$268K ———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K -67.1%——
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$574K -69.3%——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$611K +99.1%-19.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$5.01M ———
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$77.55M +67.5%——
Peer median (excluding ZVRA) -$276K+17.6%+6.5%85.5%

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.